Evidence-based guide to L-glutamine: primary enterocyte fuel, tight junction integrity (ZO-1, occludin), immune cell energetics under stress, and clinical dosing.
L-glutamine occupies an unusual position among the amino acids in the human body. It is incorporated into proteins, transports nitrogen between organs, serves as a substrate for nucleotide and amino sugar synthesis, contributes to glutathione production, and participates in renal regulation of acid–base balance. It is used particularly intensively by cells with a high metabolic turnover, including intestinal enterocytes and immune cells.
Quantitatively, glutamine is indeed one of the most abundant free amino acids in the body. Its plasma concentration is usually maintained at roughly 500–750 μmol/L, and glutamine may account for around 60% of the free amino acid pool in skeletal muscle. Muscle tissue is simultaneously the largest reservoir of glutamine and one of its major sites of synthesis.
Chemically, glutamine is a polar uncharged amino acid with an amide group in its side chain. This amide group is critically important because its nitrogen can be used in the biosynthesis of purines, pyrimidines, amino sugars, and other nitrogen-containing compounds.
Under ordinary conditions, glutamine is considered a non-essential amino acid because the body can synthesize it on its own. The enzyme glutamine synthetase combines ammonium with glutamate using energy from ATP. Skeletal muscle plays a major role in this process, while the lungs, liver, adipose tissue, and other organs also contribute to interorgan glutamine metabolism.
During severe metabolic stress, however, the situation changes. Following major trauma, severe infection, burns, and certain other critical conditions, tissue demand for glutamine increases, while plasma concentrations may fall in some patients. This is the basis for describing glutamine as a conditionally essential amino acid.
However, this classification has also generated one of the most persistent misconceptions surrounding glutamine: if glutamine levels can fall during severe illness, then providing extra glutamine must automatically improve clinical outcomes.
Modern clinical medicine has shown that this is far from true.
The gastrointestinal tract is one of the largest consumers of glutamine in the body. Human isotope studies show that during first-pass metabolism through the splanchnic tissues, approximately 54–67% of enterally administered glutamine may be extracted; in one study, around 64% of glutamine delivered through the gastrointestinal tract was taken up during the first pass, with much of the extracted carbon being oxidized.
This is why oral glutamine should not be thought of as a dose that simply travels intact to skeletal muscle or other peripheral tissues. A substantial proportion is used by the intestine and other organs within the splanchnic circulation before reaching the systemic bloodstream.
Enterocytes are indeed capable of oxidizing glutamine intensively. In human small-intestinal cells, glutamine, glutamate, and glucose are among the main substrates that increase oxygen consumption. Glutamine is converted by glutaminase into glutamate, after which its carbon skeleton can enter the tricarboxylic acid cycle through transamination and formation of α-ketoglutarate.
However, the statement that “enterocytes run almost exclusively on glutamine” would be an exaggeration. The human intestinal epithelium is metabolically flexible and can simultaneously use glutamine, glutamate, glucose, ketone bodies, and other substrates. Glutamine is an important fuel, but not the only one.
The high substrate demand of the intestinal mucosa is understandable from its architecture. The small-intestinal epithelium renews itself extremely rapidly: most differentiated epithelial cells migrate from the crypt to the villus tip and are shed within approximately three to five days.
This process requires energy, nucleotides, amino acids, and a normally functioning proliferative machinery. Glutamine contributes to several of these processes at once.
The intestinal epithelium is not merely a layer of cells. Adjacent enterocytes are connected by tight-junction complexes composed of claudins, occludin, ZO proteins, and other structural components.
Experimental studies show that glutamine availability can influence the expression and distribution of these proteins, the cytoskeleton, enterocyte proliferation, cell death, and cellular stress-signaling pathways. This physiology is the basis for the idea of using glutamine to support the intestinal barrier.
But here the same distinction applies as with many nutrients: a mechanism demonstrated in a cell culture is not the same as a clinically proven treatment.
In 2024, a systematic review and meta-analysis of ten placebo-controlled trials involving 352 participants evaluated the effect of oral glutamine on intestinal permeability. In the overall analysis, no statistically significant improvement in permeability was found. Signals of benefit appeared only in selected subgroups, including higher-dose and shorter-duration interventions, while the studies themselves were small and heterogeneous.
Therefore, the statement that “glutamine restores tight junctions and treats increased intestinal permeability” is too categorical.
A more accurate formulation is: glutamine is biologically important for normal intestinal epithelial function, and supplemental glutamine may influence permeability in certain clinical settings, but a universal effect in humans has not been demonstrated.
Increased intestinal permeability is a real physiological phenomenon. It can occur in some infections, inflammatory bowel diseases, celiac disease, severe systemic illnesses, after certain medications, and during extreme physical exertion.
However, the popular term “leaky gut syndrome” is often used much more broadly—as an explanation for fatigue, skin eruptions, food reactions, anxiety, autoimmune disease, and dozens of other symptoms. In this form, it is not a well-validated standalone clinical diagnosis with a universal laboratory test and a standard “glutamine treatment protocol.”
Serum “zonulin” should be interpreted particularly cautiously. Studies have shown that several widely used commercial ELISA assays do not actually measure true zonulin—prehaptoglobin-2—but instead react with other proteins, including complement-related proteins. In some studies, values from these “zonulin” assays also correlated poorly with functional sugar permeability tests.
Therefore, the sequence “test zonulin → find it elevated → prescribe glutamine” is scientifically very unreliable.
Fecal calprotectin, by contrast, is a useful marker of intestinal inflammation, particularly in inflammatory bowel disease, but it is not a test of intestinal permeability. This is how it is used in modern gastroenterology guidelines.
One of the most striking glutamine trials was conducted not in people with an abstract diagnosis of “leaky gut,” but in a very specific patient population.
The double-blind placebo-controlled trial enrolled people who developed diarrhea-predominant irritable bowel syndrome—IBS-D—after an intestinal infection and who also had objectively documented increased intestinal permeability.
Patients received 5 g of glutamine three times daily—a total of 15 g/day—for eight weeks. The primary endpoint was achieved by 79.6% of participants in the glutamine group compared with only 5.8% in the placebo group. Stool frequency, stool form, overall IBS symptom severity, and intestinal permeability also improved.
This is a genuinely strong clinical signal.
However, it applies to a very specific population: post-infectious IBS-D plus documented increased intestinal permeability. The findings cannot automatically be extrapolated to constipation-predominant IBS, mixed IBS, functional bloating, nonspecific “food intolerances,” or anyone with abdominal pain.
In addition, such an unusually large difference between groups requires independent replication.
The study therefore points to a potentially important therapeutic niche rather than establishing glutamine as a universal treatment for irritable bowel syndrome.
Inflammatory bowel disease seems, at first glance, like an ideal target for glutamine: impaired barrier function, inflammation, accelerated cell turnover, and potentially increased substrate demand in the intestinal mucosa.
But clinical trials have been far less impressive than the experimental biology.
A systematic review of clinical studies in Crohn’s disease and ulcerative colitis concluded that glutamine supplementation overall did not convincingly affect disease course, inflammatory activity, symptoms, anthropometric measures, intestinal permeability, or oxidative stress markers.
Cochrane also found insufficient evidence that glutamine is effective for inducing remission in active Crohn’s disease.
Therefore, the claim that “glutamine supports the mucosa during remission in Crohn’s disease and ulcerative colitis” is biologically plausible but clinically insufficiently supported.
In inflammatory bowel disease, glutamine should not replace anti-inflammatory therapy, biologic agents, immunomodulators, or other treatments with demonstrated effects on disease progression.
Activated lymphocytes, macrophages, and other immune cells do indeed use glutamine intensively.
One reason is that glutamine’s amide nitrogen is required for the synthesis of purine and pyrimidine nucleotides. A rapidly dividing lymphocyte must replicate DNA, synthesize RNA and proteins, and reorganize its energy metabolism, while glutamine can simultaneously provide both nitrogen and carbon for these processes.
Therefore, when glutamine is severely restricted in cell culture, immune-cell function is genuinely impaired.
But in the body of a healthy person, glutamine availability is usually not the metabolic “bottleneck” that can simply be overcome with an additional 5–10 g of powder.
Sports nutrition literature illustrates this well. A systematic review and meta-analysis of studies in athletes found no overall significant effect of glutamine on immune function, aerobic performance, or body composition.
Thus, the statement “glutamine is a fuel for immune cells” is correct.
The statement “therefore glutamine supplementation strengthens immunity” is a separate clinical hypothesis and cannot be considered established for healthy individuals.
Glutamine is genuinely connected to the antioxidant system.
Inside the cell, it can be converted into glutamate. Glutamate then combines with cysteine through the action of glutamate-cysteine ligase, after which glycine is added to produce reduced glutathione—GSH.
Glutathione is one of the most important intracellular thiol antioxidants and is involved not only in neutralizing oxidants but also in redox signaling, xenobiotic detoxification, and regulation of cellular processes.
However, this relationship is sometimes oversimplified into “more glutamine = more glutathione.”
In reality, GSH synthesis is regulated more complexly. One of the major rate-limiting factors is often the availability of cysteine, together with the activity of glutamate-cysteine ligase.
In a small study of healthy volunteers, 0.3 g/kg/day of glutamine for ten days increased plasma glutamine and glutamate concentrations but did not increase whole-blood glutathione. The authors concluded that glutathione synthesis was constrained by factors beyond glutamine availability.
So glutamine is one metabolic precursor of glutathione, but oral supplementation does not automatically increase the body’s antioxidant defenses.
One of glutamine’s most interesting functions occurs in the kidneys.
During metabolic acidosis, proximal tubular cells markedly increase glutamine uptake and metabolism. Through renal ammoniagenesis, one molecule of glutamine can ultimately generate two ammonium ions and two equivalents of bicarbonate.
Ammonium is excreted in the urine, helping the body eliminate an acid load, while newly generated bicarbonate returns to the systemic circulation and helps restore buffering capacity.
Modern physiology has also refined the older textbook model in which NH₃ simply diffuses passively into the tubular lumen and becomes “trapped” there as NH₄⁺. Ammonia and ammonium handling involves specialized transport proteins and complex recycling along different segments of the nephron.
This is an excellent example of how fundamentally important glutamine is to human physiology—and at the same time, an example of a function for which a healthy person does not need to consume glutamine powder.
During the 1990s and early 2000s, glutamine became one of the most popular bodybuilding supplements. The marketing logic sounded persuasive: glutamine makes up a large proportion of the free amino acid pool in muscle, hard exercise changes its concentration, therefore extra glutamine should accelerate muscle growth and recovery.
This hypothesis largely failed clinical testing.
A systematic review of 47 studies and meta-analysis of 25 trials found no convincing improvement in aerobic performance, body composition, or most immune-related outcomes in athletes.
The fact that glutamine is present in large quantities in muscle does not mean that additional glutamine intake is a limiting factor for muscle hypertrophy.
When high-quality protein intake is adequate, total essential amino acid intake, energy availability, training stimulus, and recovery are much more important.
Healthy strength athletes therefore should not view glutamine as an independent anabolic agent.
During prolonged running, especially in the heat, blood flow is genuinely redistributed toward working muscles and the skin. Splanchnic perfusion decreases, body temperature rises, and mechanical stress on the gastrointestinal tract increases. Together, these factors can increase markers of enterocyte injury and intestinal permeability. Systematic reviews confirm that prolonged exercise can increase markers of intestinal damage and permeability.
Several small experiments suggest that glutamine may attenuate some of these changes.
In studies of running in hot conditions, relatively large doses were used—for example 0.25, 0.5, or 0.9 g/kg of fat-free mass before 60 minutes of running. In some trial conditions, markers of intestinal permeability or epithelial damage were reduced.
But two points are important.
First, these studies mainly evaluated biomarkers, not rates of clinically meaningful “runner’s diarrhea” or the ability to complete an ultramarathon.
Second, the evidence base consists of very small studies. Some individual experiments included only seven to ten participants.
Therefore, it is not currently justified to claim that “5–10 g of glutamine before a race has been proven to prevent splanchnic ischemia, endotoxemia, and diarrhea.”
A more accurate formulation is: glutamine is a promising nutritional intervention for reducing certain markers of intestinal stress during prolonged exercise, particularly in the heat, but the optimal dose and clinical significance remain uncertain.
The older sports-immunology model proposed that after a marathon or other extreme endurance event there is a period of temporary immunosuppression—the so-called open window—during which athletes are especially vulnerable to infection.
Glutamine was therefore widely promoted as a strategy to prevent upper respiratory infections.
One older study did report that during the week after strenuous exercise, participants receiving glutamine were more likely to report being free of infection symptoms than those receiving placebo.
However, later literature did not confirm a consistent immune-protective effect. A meta-analysis of sports studies found no overall improvement in immune function with glutamine supplementation.
Moreover, the “open-window” model itself is now viewed more cautiously. A decrease in circulating lymphocyte numbers after exercise may reflect redistribution of immune cells into tissues rather than true immune paralysis. Modern reviews emphasize that the link between these short-lived changes in blood and an actual increase in infection risk is much weaker than previously assumed.
Glutamine therefore cannot be considered a proven strategy for preventing respiratory infections after endurance exercise.
Oncology presents a particularly complex picture.
On the one hand, chemotherapy and radiotherapy damage rapidly renewing mucosal tissues, making glutamine seem like a biologically plausible support strategy.
A meta-analysis of 16 randomized trials found that glutamine reduced the risk of severe grade III–IV oral mucositis.
MASCC/ISOO guidelines allow the use of oral glutamine for prevention of oral mucositis in patients with head and neck cancer receiving combined chemoradiotherapy, while recommending against parenteral glutamine in hematopoietic stem-cell transplantation.
However, broader ESPEN oncology guidance remains cautious: evidence is insufficient to recommend glutamine universally during standard cytotoxic or targeted therapies, or for prevention of radiation enteritis, diarrhea, stomatitis, esophagitis, or skin toxicity.
This distinction matters because oral mucositis, intestinal mucositis, and radiation enteritis are not the same condition.
For example, a meta-analysis of 13 randomized trials in radiation enteritis found no significant improvement in disease severity or symptoms with glutamine.
At the same time, a more recent meta-analysis in colorectal cancer reported a reduction in diarrhea during chemotherapy or chemoradiotherapy, but graded the certainty of evidence as low.
It is therefore incorrect to say that “glutamine prevents chemotherapy- and radiation-induced intestinal injury.” The effect depends on tumor type, treatment, the anatomical site of mucositis, the form of glutamine used, and the clinical endpoint being measured.
Many cancer cells do indeed reprogram their metabolism to use glutamine intensively.
Glutamine can provide carbon for replenishing tricarboxylic acid cycle intermediates, nitrogen for nucleotide and amino acid synthesis, and support for redox homeostasis. Some tumors demonstrate marked dependence on glutamine metabolism, and enzymes within these pathways are being investigated as potential therapeutic targets.
However, the next conclusion—“therefore oral glutamine inevitably accelerates tumor growth”—has not been demonstrated.
A human organism and a tumor cell culture are fundamentally different systems. In a patient with cancer, glutamine is simultaneously used by the intestine, immune cells, liver, muscle, and the tumor itself. Older clinical reviews did not find convincing evidence that nutritional glutamine accelerates tumor growth, but contemporary guidelines still do not consider the evidence strong enough to support universal supplementation.
Therefore, active cancer is not a reason to automatically label every molecule of glutamine as “forbidden,” but neither is it an appropriate setting for self-prescribed therapeutic doses.
The decision should depend on the specific cancer treatment protocol and be discussed with the treating oncology team.
Critical care provided the most important lesson in the history of glutamine supplementation.
For years, the logic seemed almost flawless: glutamine concentrations often fall in critically ill patients; immune cells and the intestine need glutamine intensely; therefore, the deficit should be replaced rapidly.
Then came the REDOXS trial.
The randomized study enrolled 1,223 critically ill adults with multiorgan failure who were receiving mechanical ventilation. Glutamine was started very early and given in high doses by both enteral and intravenous routes.
At 28 days, mortality showed a trend toward being higher in the glutamine group—32.4% versus 27.2%. In-hospital mortality and six-month mortality were statistically higher among patients receiving glutamine. Infectious complications and organ failure were not reduced.
REDOXS dismantled the simple equation “low nutrient level during illness = it must immediately be replaced.”
A low metabolite concentration may be not only a cause of disease but also a marker of disease severity or part of an adaptive response.
For many years, severe burns were considered one of the strongest indications for supplemental glutamine. Small early trials suggested fewer infectious complications, and the practice entered clinical recommendations.
However, the large RE-ENERGIZE trial changed the picture.
In this study, 1,200 patients with severe burns received enteral glutamine at 0.5 g/kg/day or placebo. Median time to discharge alive was 40 days in the glutamine group and 38 days in the placebo group, with no statistically significant benefit. Six-month mortality also did not differ substantially.
The 2023 ESPEN practical guideline formally retained a recommendation for enteral glutamine in burns involving more than 20% of body surface area, but explicitly noted that this recommendation had been challenged by the largest randomized trial and required reconsideration. For most other ICU patients, supplemental enteral glutamine is not recommended; in unstable critical illness, especially with hepatic or renal failure, parenteral glutamine should not be used.
The updated 2025 ESPEN surgical guideline became even more cautious: parenteral glutamine should not be administered in patients with severe hepatic, renal, or multiorgan failure, and routine supplemental enteral glutamine in surgery is also not recommended.
This is one of the most important lessons of the entire topic: conditional essentiality does not automatically mean that pharmacological doses are beneficial.
After oral intake, most glutamine does not travel unchanged to skeletal muscle.
Human studies have found first-pass splanchnic extraction of approximately 54–67%, and under certain experimental conditions even higher. A substantial proportion of extracted glutamine is oxidized directly within splanchnic tissues.
Therefore, the statement that “only 30% of glutamine is absorbed” is also incorrect. Absorption from the intestinal lumen and the amount of unchanged glutamine that appears in the systemic circulation are two different concepts.
Glutamine may be efficiently absorbed into an enterocyte and then immediately metabolized by that cell.
This is why oral glutamine is more logically viewed as a substrate that strongly interacts with splanchnic metabolism than as a way to directly “flood the muscles with amino acids.”
There is no convincing clinical evidence that glutamine must always be taken strictly on an empty stomach 20–30 minutes before meals.
In fact, human studies have shown that splanchnic extraction of free glutamine and glutamine provided as part of dietary protein can be comparable.
If a specific clinical study used fasting administration, that protocol can be reproduced when following the same treatment regimen. But this should not be turned into a universal pharmacokinetic rule for every glutamine product.
For most people, gastrointestinal tolerance is likely to be more practically relevant.
Glutamine is indeed less stable in aqueous solution than many other amino acids, and the rate of degradation increases with temperature and depends on pH.
But the popular statement that “in hot water glutamine instantly turns into glutamate and ammonia” is incorrect.
Stability studies have shown that at room temperature glutamine degrades relatively slowly in water. One investigation detected ammonia formation during degradation without a corresponding increase in glutamate, while another identified 5-pyrrolidone-2-carboxylic acid—pyroglutamate—as a degradation product.
Temperature does accelerate degradation, especially with substantial heating, so dissolving the powder in boiling water and then storing the solution for a long time makes little sense.
A practical approach is to prepare it immediately before use in cool or room-temperature water or another suitable liquid. This is also the method specified in the official prescribing information for the prescription L-glutamine product Endari.
This is an issue of product stability, not a dangerous “conversion of glutamine into toxic glutamate” after a few minutes in a warm drink.
There is no single clinically established dose of glutamine for “intestinal repair.”
Different studies addressed different clinical questions.
In post-infectious IBS-D with documented increased intestinal permeability, the dose was 5 g three times daily for eight weeks.
In experiments evaluating exercise-induced intestinal permeability, doses as high as 0.9 g/kg of fat-free mass were used before running—substantially more than the standard 5–10 g often recommended in sports supplements.
In oncology trials, protocols in the range of approximately 10–30 g/day have been used, but results depended on the specific form of mucositis and the treatment setting.
The prescription L-glutamine product Endari, approved in the United States to reduce acute complications of sickle cell disease, is administered at 5–15 g twice daily depending on body weight, up to 30 g/day, and has been studied during long-term treatment.
These doses are not interchangeable.
The dose of a prescription drug used in sickle cell disease is not a “gut health dose,” and the dose used in a heat-exercise experiment is not a treatment protocol for IBS.
Oral glutamine is generally well tolerated in most people.
Experience with the prescription product Endari is particularly useful for evaluating long-term safety: patients received up to 30 g/day for approximately 48 weeks, with some followed for a year or longer. The most frequently reported adverse events included constipation, nausea, headache, and abdominal pain, although many of these symptoms also occurred in the placebo group.
Therefore, the claim that “safety has only been demonstrated up to 14 g/day” is incorrect.
But the opposite extreme is also wrong: high doses should not be assumed safe for every patient.
The official Endari prescribing information specifically notes that pharmacokinetics have not been studied in patients with renal or hepatic impairment, and patients with renal insufficiency and uncontrolled liver disease were excluded from the pivotal clinical trial.
Glutamine metabolism is closely linked to ammonia, making this an important issue in cirrhosis.
So-called oral glutamine challenge studies show that 20 g of glutamine can markedly increase ammonia concentrations in patients with cirrhosis and worsen sensitive psychometric measures, especially when portosystemic clearance is impaired. This is why glutamine loading was historically used as a way to investigate susceptibility to hepatic encephalopathy.
This provides a strong rationale for caution in patients with decompensated cirrhosis, portosystemic shunting, or previous episodes of hepatic encephalopathy.
However, describing oral glutamine as “absolutely contraindicated in all liver disease” would also be inaccurate.
A more appropriate statement is: in severe hepatic failure, and particularly when hyperammonemia is a concern, high-dose glutamine should not be self-administered. In critical care, modern guidelines specifically advise against supplemental parenteral glutamine in severe hepatic failure.
Severe chronic kidney disease also requires caution.
This is not because “every amino acid turns into a uremic toxin and is therefore absolutely prohibited.” Contemporary nutritional management of kidney disease is much more nuanced, and protein requirements depend on CKD stage, dialysis status, catabolism, and comorbid conditions.
However, pharmacological quantities of free amino acids should not be added without supervision in severe renal impairment.
In a small study of healthy older adults, 0.5 g/kg/day of glutamine for 14 days did not cause clinically significant toxicity, although small changes in urea, creatinine, and estimated GFR were observed.
In guidelines for severely ill surgical and critical-care patients, the combination of significant renal failure and supplemental parenteral glutamine is already considered a setting in which such therapy should not be used.
Although low plasma glutamine concentrations have been described in critical illness, there is no widely accepted outpatient diagnostic algorithm for “glutamine deficiency” comparable to ferritin for iron status or vitamin B12 for cobalamin status.
Plasma glutamine depends on interorgan metabolism, recent exercise, catabolism, hormones, acid–base balance, nutrition, and numerous other variables.
More importantly, critical-care experience has shown that simply detecting a low glutamine concentration does not mean that raising it will improve clinical outcomes.
This is a broader principle in nutrition science: a biomarker, a physiological requirement, and a therapeutic target are not the same thing.
For a healthy person consuming adequate protein, supplemental glutamine is usually unnecessary for maintaining the intestinal epithelium, supporting immunity, or building muscle.
That does not make glutamine’s physiological role any less fundamental. It genuinely is one of the key substrates for the intestine and immune cells, a nitrogen donor for biosynthesis, and a central molecule in interorgan nitrogen metabolism.
But the healthy human body already produces it in large quantities.
One of the most interesting outpatient signals remains post-infectious IBS-D with documented increased intestinal permeability, where one high-quality randomized trial found a marked benefit from 15 g/day for eight weeks. However, this result should not yet be converted into a universal protocol for all IBS or nonspecific gastrointestinal complaints.
In sports, glutamine is not a convincing anabolic agent and has not been proven to be a universal immune protector. Preliminary evidence suggests that it may reduce certain markers of intestinal damage during running in the heat, but this remains a specialized area of exercise physiology rather than a ready-made recommendation for all marathon runners.
In Crohn’s disease and ulcerative colitis, convincing therapeutic benefit has not been demonstrated.
In oncology, the situation depends on the specific clinical question: oral glutamine may have a place in selected protocols for preventing oral mucositis, but evidence is insufficient for broad use during chemotherapy and radiotherapy, and self-prescribing is inappropriate.
And in critically ill patients, high-dose glutamine cannot be approached according to the principle “the more severe the deficiency, the more we should give”: REDOXS demonstrated just how dangerous such reasoning can be.
With glutamine, it is particularly easy to construct a completely correct biochemical chain:
glutamine is required by enterocytes;enterocytes form the intestinal barrier;glutamine contributes to nucleotide synthesis;activated immune cells use it intensively;it can provide glutamate for glutathione synthesis;the kidneys use it for ammoniagenesis and bicarbonate generation.
All of that is true.
But it does not follow that:
glutamine treats “leaky gut”;glutamine boosts immunity;glutamine builds muscle;glutamine treats Crohn’s disease;glutamine prevents infections after a marathon;glutamine is necessarily beneficial in sepsis.
Between biochemical necessity and a clinical effect lie substrate concentration, enzyme regulation, the condition of the specific tissue, the cause of disease, dose, route of administration, and baseline nutritional status.
L-glutamine is one of the central amino acids of human interorgan metabolism and an important substrate for the intestinal epithelium, immune cells, and kidneys. But the molecule’s fundamental physiological role does not make it a universal supplement “for the gut and immunity.” In healthy people, endogenous synthesis is generally sufficient; in selected diseases there are interesting but highly specific signals of benefit; and in severe critical illness, high-dose administration may be not only ineffective but harmful. The central task when discussing glutamine is therefore to clearly distinguish physiological necessity from the proven effect of a specific dose in a specific patient population.
This material is for educational purposes only and does not replace medical diagnosis, treatment, or individualized medical advice.
Controlled trials show no significant hypertrophy benefit in healthy lifters. Its proven clinical role centers on intestinal barrier repair and mucosal recovery.
Take 5 g of L-glutamine powder dissolved in room-temperature water 1–2 times daily on an empty stomach. Avoid hot liquids, which degrade the molecule.